Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

313 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An Open-Label, Single-Arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease.
Doki N, Toyosaki M, Shiratori S, Osumi T, Okada M, Kawakita T, Sawa M, Ishikawa T, Ueda Y, Yoshinari N, Nakahara S. Doki N, et al. Among authors: osumi t. Transplant Cell Ther. 2021 Oct;27(10):867.e1-867.e9. doi: 10.1016/j.jtct.2021.05.019. Epub 2021 Jun 6. Transplant Cell Ther. 2021. PMID: 34102349 Free article. Clinical Trial.
The effect of graft-versus-host disease on outcomes after allogeneic stem cell transplantation for refractory lymphoblastic lymphoma in children and young adults.
Mitsui T, Fujita N, Koga Y, Fukano R, Osumi T, Hama A, Koh K, Kakuda H, Inoue M, Fukuda T, Yabe H, Takita J, Shimada A, Hashii Y, Sato A, Atsuta Y, Kanda Y, Suzumiya J, Kobayashi R. Mitsui T, et al. Among authors: osumi t. Pediatr Blood Cancer. 2020 Apr;67(4):e28129. doi: 10.1002/pbc.28129. Epub 2019 Dec 26. Pediatr Blood Cancer. 2020. PMID: 31876367
A Phase I/II Study of Crizotinib for Recurrent or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma and a Phase I Study of Crizotinib for Recurrent or Refractory Neuroblastoma : Study Protocol for a Multicenter Single-arm Open-label Trial.
Sekimizu M, Osumi T, Fukano R, Koga Y, Kada A, Saito AM, Mori T. Sekimizu M, et al. Among authors: osumi t. Acta Med Okayama. 2018 Aug;72(4):431-436. doi: 10.18926/AMO/56184. Acta Med Okayama. 2018. PMID: 30140094 Free article.
A Multicenter, Open-label, Clinical Trial to Assess the Effectiveness and Safety of Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-intensity Conditioning in Relapsed/refractory Anaplastic Large-cell Lymphoma in Children.
Kada A, Fukano R, Mori T, Kamei M, Tanaka F, Ueyama J, Sekimizu M, Osumi T, Mori T, Koga Y, Ohki K, Fujita N, Mitsui T, Saito AM, Hashimoto H, Kobayashi R. Kada A, et al. Among authors: osumi t. Acta Med Okayama. 2020 Feb;74(1):89-94. doi: 10.18926/AMO/57959. Acta Med Okayama. 2020. PMID: 32099255 Free article.
Prospective Study of Allogeneic Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide and Antithymocyte Globulin from HLA-Mismatched Related Donors for Nonmalignant Diseases.
Osumi T, Yoshimura S, Sako M, Uchiyama T, Ishikawa T, Kawai T, Inoue E, Takimoto T, Takeuchi I, Yamada M, Sakamoto K, Yoshida K, Kimura Y, Matsukawa Y, Matsumoto K, Imadome KI, Arai K, Deguchi T, Imai K, Yuza Y, Matsumoto K, Onodera M, Kanegane H, Tomizawa D, Kato M. Osumi T, et al. Biol Blood Marrow Transplant. 2020 Nov;26(11):e286-e291. doi: 10.1016/j.bbmt.2020.08.008. Epub 2020 Aug 14. Biol Blood Marrow Transplant. 2020. PMID: 32798657 Free article.
313 results